Search

everythinglearnresearchcommunity

for

Search:↓

Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.

Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.

IVIG therapy significantly improved symptoms in a patient with APS-2 and SPS.

Janus kinase inhibitors may effectively treat resistant scalp conditions like folliculitis decalvans and dissecting cellulitis.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

Rituximab leads to longer remission and fewer side effects than cyclophosphamide.

Ruxolitinib cream shows promise for vitiligo, and early melanoma diagnosis is crucial.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.

Baricitinib is the most effective treatment for alopecia areata.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

Omalizumab may cause temporary hair loss, especially in women aged 18-60.

JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.

Secukinumab treatment may cause HBV reactivation and hair discoloration.

New treatments for lupus show promise, but more research is needed, especially for children.

Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.

Patients with acute and subacute skin lupus respond faster to belimumab than those with chronic skin lupus.

Tofacitinib effectively improved severe skin symptoms in a patient with Hypohidrotic Ectodermal Dysplasia.

JAK inhibitors offer new hope for treating severe alopecia areata.

Janus Kinase Inhibitors are promising new treatments for various skin conditions due to their effectiveness and safety.

Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.

Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.

No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.

Biosimilars lower costs but don't significantly improve access.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

Upadacitinib effectively treats pyoderma gangrenosum.